JIBTVA  Vol.2 No.2 , April 2013
Towards a Pan-Anti-Allergy Vaccine
ABSTRACT
Allergic manifestations affect 20% - 30% of the population in industrialized countries. The global market for asthma and allergy medications has been estimated to exceed USD 6 billion, since 40% of the human population has some form of IgE sensitization to diverse proteins. Most therapeutic intervention strategies cope with the symptoms of allergy without eliminating the underlying cause and many are associated with undesirable and often long-term debilitating side effects. We designed a peptide immunogen encompassing sequences of the human Cε2-3 linker region to prime rat (Rattus norvegicus) immune systems, we then designed a chimeric human-dog-human IgE antibody and used it to boost the immune system and produce high-affinity antibodies that targets native IgE. The investigation showed that this peptide immunogen elicit the formation of antibodies recognizing the native IgE of human, canine and equine origin. The current investigation describes novel approaches aimed at the development of safe anti-allergy vaccines based on active immunization with IgE-derived peptides that are involved in the complementary interaction with the high affinity receptor. The immunization strategy was successful but did not fully work as predicted, thus we propose that peptides described in the current study may lead to the development of a pananti-allergy vaccine with applications for the treatment of all IgE-mediated allergic response independent of the nature of the offending allergen.

Cite this paper
S. Sabban, H. Ye, A. Vratimos, A. Moir, A. Wheeler and B. Helm, "Towards a Pan-Anti-Allergy Vaccine," Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol. 2 No. 2, 2013, pp. 15-27. doi: 10.4236/jibtva.2013.22003.
References
[1]   R. Pawankar, G. W. Canonica, S. T. Holgate and R. F. Lockey, “White Book on Allergy 2011-2012 Executive Summary,” World Health Organization, Geneva, 2012.

[2]   D. R. Stanworth, J. H. Humphrey, H. Bennich and S. G. Johansson, “Inhibition of Prausnitz-Küstner Reaction by Proteolytic-Cleavage Fragments of a Human Myeloma Protein of Immunoglobulin Class E,” Lancet, Vol. 2, No. 7558, 1968, pp. 17-18. doi:10.1016/S0140-6736(68)92889-4

[3]   P. J. Barnes, “Therapeutic Strategies for Allergic Diseases,” Nature, Vol. 402, Suppl. B, 1999, pp. 31-38.

[4]   B. A. Helm, A. C. Spivey and E. A. Padlan, “Peptide Blocking of IgE/Receptor Interaction: Possibilities and Pitfalls,” Allergy, 1997, Vol. 52, No. 12, pp. 1155-1169. doi:10.1111/j.1398-9995.1997.tb02518.x

[5]   W. A. Hook, et al., “Monoclonal Antibodies to Human IgE,” Federation Proceedings, Vol. 40, 1981.

[6]   L. G. Presta, S. J. Lahr, R. L. Shields, J. P. Porter, C. M. Gorman, B. M. Fendly and P. M. Jardieu, “Humanization of an Antibody Directed against IgE,” Journal of Immunology, Vol. 151, No. 5, 1993, pp. 2623-2632.

[7]   S. Laffer, E. Hogbom, K. H. Roux, W. R. Sperr, P. Valent, H. C. Bank, L. Vangelista, F. Kricek, D. Kraft, H. Gronlund and R. Valenta, “A Molecular Model of Type I Allergy: Identification and Characterization of a Nonana-phylactic Anti-Human IgE Antibody Fragment that Blocks the IgE-FcεRI Interaction and Reacts with Receptor-Bound IgE,” The Journal of Allergy and Clinical Immunology, Vol. 108, No. 3, 2001, pp. 409-416. doi:10.1067/mai.2001.117593

[8]   S. Laffer, C. Lupinek, I. Rauter, M. Kneidinger, A. Drescher, J. H. Jordan, M. T. Krauth, P. Valent, F. Kricek, S. Spitzauer, H. Englund and R. Valenta, “A High-Affinity Monoclonal Anti-IgE Antibody for Depletion of IgE and IgE-Bearing Cells,” Allergy, Vol. 63, No. 6, 2008, pp. 695-702. doi:10.1111/j.1398-9995.2008.01664.x

[9]   S. C. Garman, B. A. Wurzburg, S. S. Tarchevskaya, J.-P. Kinet and T. S. Jardetzky, “Structure of the Fc Fragment of Human IgE Bound to Its High-Affinity Receptor FcεRIα,” Nature, Vol. 406, 2000, pp. 259-266. doi:10.1038/35018500

[10]   A. W. Wheeler, J. S. Marshall and J. T. Ulrich, “A Th-1 Inducing Adjuvant, MPL, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines,” International Archives of Allergy and Immunology, Vol. 126, No. 2, 2001, pp. 135-139. doi:10.1159/000049504

[11]   C. Y. Wang, A. M. Walfield, X. Fang, B. Hammerberg, J. Ye, M. L. Li, F. Shen, M. Shen, V. Alexander and D. W. MacGlashan, “Synthetic IgE Peptide Vaccine for Immunotherapy of Allergy,” Vaccine, Vol. 21, No. 15, 2003, pp. 1580-1590. doi:10.1016/S0264-410X(02)00732-6

[12]   F. R. Ali and M. Larché, “Peptide-Based Immunotherapy: A Novel Strategy for Allergic Disease,” Expert Review of Vaccines, Vol. 4, No. 6, 2005, pp. 881-889. doi:10.1586/14760584.4.6.881

[13]   A. Ledin, K. Bergvall, N. S. Hillbertz, H. Hansson, G. Andersson, A. Hedhammar and L. Hellman, “Generation of Therapeutic Antibody Responses against IgE in Dogs, an Animal Species with Exceptionally High Plasma IgE levels,” Vaccine, Vol. 24, No. 1, 2006, pp. 66-74. doi:10.1016/j.vaccine.2005.07.052

[14]   V. Niederberger and R. Valenta, “Molecular Approaches for New Vaccines against Allergy,” Expert Review of Vaccines, Vol. 5, No. 1, 2006, pp. 103-110. doi:10.1586/14760584.5.1.103

[15]   Z. Peng, Q. Liu, Q. Wang, E. Rector, Y. Ma and R. Warrington, “Novel IgE Peptide-Based Vaccine Prevents the Increase of IgE and Down-Regulates Elevated IgE in Rodents,” Clinical & Experimental Allergy, Vol. 37, No. 7, 2007, pp. 1040-1048. doi:10.1111/j.1365-2222.2007.02741.x

[16]   J. Johansson and L. Hellman, “Modifications Increasing the Efficacy of Recombinant Vaccines; Marked Increase in Antibody Titers with Moderately Repetitive Variants of a Therapeutic Allergy Vaccine,” Vaccine, Vol. 25, No. 9, 2007, pp. 1676-1682. doi:10.1016/j.vaccine.2006.10.055

[17]   L. F. Pacios, L. Tordesillas, J. Cuesta-Herranz, E. Compes, R. Sánchez-Monge, A. Palacín, G. Salcedo and A. Díaz-Perales, “Mimotope Mapping as a Complementary Strategy to Define Allergen IgE-Epitopes: Peach Pru p 3 Allergen as a Model,” Molecular Immunology, Vol. 45, No. 8, 2008, pp. 2269-2276. doi:10.1016/j.molimm.2007.11.022

[18]   L. T. Hellman, S. Persson and A. Jansson, “Allergy,” Vaccines US Patent No. 2009/0191268 A1, 2009.

[19]   T. Francis Jr., “The Current Status of the Control of Influenza,” Annals of Internal Medicine, Vol. 43, No. 3, 1955, pp. 534-538. doi:10.7326/0003-4819-43-3-534

[20]   T. Francis Jr., “On the Doctrine of Original Antigenic Sin,” Proceedings of the American Philosophical Society, Vol. 104, No. 6, 1960, pp. 572-578.

[21]   A. P. M. Wilson, C. E. Pullar, A. M. Camp and B. A. Helm, “Human IgE Mediates Stimulus Secretion Coupling in Rat Basophilic Leukemia Cells Transfected with the Alpha Chain of the Human High-Affinity Receptor,” European Journal of Immunology, Vol. 23, No. 1, 1993, pp. 240-244. doi:10.1002/eji.1830230137

[22]   J. M. Hunter, A. P. Vratimos, J. E. Housden and B. A. Helm, “Generation of Canine-Human Fc IgE Chimeric Antibodies for the Determination of the Canine Domain of Interaction with Fc Epsilon RI Alpha,” Molecular Immunology, Vol. 45, No. 8, 2008, pp. 2262-2268. doi:10.1016/j.molimm.2007.11.015

[23]   S. Sabban, “Development of an in Vitro Model System for Studying the Interaction of Equus caballus IgE with Its High-Affinity FcεRI Receptor,” Ph.D. Thesis, The University of Sheffield, Sheffield, 2011, http://etheses.whiterose.ac.uk/2040/2/Sabban%2C_Sari.pdf

[24]   S. Sabban, H. Ye and B. A. Helm, “Development of an in Vitro Model System for Studying the Interaction of Equus caballus IgE with Its High-Affinity Receptor FcεRI,” Veterinary Immunology and Immunopathology, Vol. 153, No. 1-2, 2013, pp. 6-10. doi:10.1016/j.vetimm.2013.01.008

[25]   M. S. Neuberger, G. T. Williams, E. B. Mitchell, S. S. Jouhal, J. G. Flanagan and T. H. Rabbitts, “A Hapten-Specific Chimaeric IgE Antibody with Human Physio-logical Effector Function,” Nature, Vol. 314, No. 6008, 1985, pp. 268-270. doi:10.1038/314268a0

[26]   S. L. Morrison, M. J. Johnson, L. A. Herzenberg and V. T. Oi, “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains,” Proceedings of the National Academy of Sciences of the USA, Vol. 81, No. 21, 1984, pp. 6851-6855. doi:10.1073/pnas.81.21.6851

[27]   I. Sayers, S. A. Cain, J. R. M. Swan, M. A. Pickett, P. J. Watt, S. T. Holgate, E. A. Padlan, P. Schuck and B. A. Helm, “Amino Acid Residues That Influence FcεRI-Mediated Effector Functions of Human Immunoglobulin E,” Biochemistry, Vol. 37, No. 46, 1998, pp. 16152-16164.

[28]   G. Kohler and C. Milstein, “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,” Nature, Vol. 256, No. 5517, 1975, pp. 495-497. doi:10.1038/256495a0

 
 
Top